Following disruptions in routine immunisation programmes because of the pandemic, there is an urgent need to catch-up on non-COVID-19 school immunisations such as human papillomavirus (HPV) and meningitis (MenACWY) vaccinations, and there may be a need to offer other routine vaccines (such as mumps, measles and rubella (MMR)) in the school setting as part of overall recovery. In addition,
for 2021 to 2022, the childhood influenza programme has been extended in the expectation that influenza activity may be earlier and more pronounced this year. The health benefits from these various non-COVID-19 school-based immunisation programmes are well established, and some may provide the last effective opportunity to complete an individual’s immunisation course and provide timely and/or lifelong protection. Further deferral of the delivery of these immunisation programmes may be associated with permanent decreases in uptake of these vaccines in affected school age cohorts.
Delivery of a COVID-19 vaccine programme for children and young people is likely to be disruptive to education in the short-term, particularly if school premises are used for vaccination. Adverse reactions to vaccination (such as fevers) may also lead to time away from education for some individuals.
Considerable additional resource will be required to minimise the operational impacts of a COVID-19 vaccine programme on the wider health of children and young people.